shutterstock_1086968018_jarretera-2
Jarretera / Shutterstock.com
10 March 2020AmericasRory O'Neill

FDA, FTC send message to biologics makers at competition workshop

US drug and antitrust regulators have signalled their intent to crack down on anti-competitive behaviour in the biologics and biosimilar industries, in an effort to bring down prices.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
4 February 2020   US competition regulators will increase scrutiny of biologic and biosimilar-related patent settlements, as they look to crack down on antitrust violations.
Big Pharma
11 February 2020   Clarivate Analytics has released its annual “drug to watch” list, compiled through its Cortellis database of life sciences-focused research and development data.

More on this story

Americas
4 February 2020   US competition regulators will increase scrutiny of biologic and biosimilar-related patent settlements, as they look to crack down on antitrust violations.
Big Pharma
11 February 2020   Clarivate Analytics has released its annual “drug to watch” list, compiled through its Cortellis database of life sciences-focused research and development data.

More on this story

Americas
4 February 2020   US competition regulators will increase scrutiny of biologic and biosimilar-related patent settlements, as they look to crack down on antitrust violations.
Big Pharma
11 February 2020   Clarivate Analytics has released its annual “drug to watch” list, compiled through its Cortellis database of life sciences-focused research and development data.